Sector News

Roche says will buy U.S. maker of prenatal Down syndrome test

December 2, 2014
Life sciences
(Reuters) – Roche said on Tuesday it will acquire San Jose, CA-based Ariosa Diagnostics, Inc., a molecular diagnostics firm which makes a prenatal test to assess the risk of Down syndrome and other genetic abnormalities.
 
Financial details of the deal were not disclosed.
 
“The acquisition of Ariosa is another example of Roche’s commitment to advanced molecular diagnostics,” Roche diagnostics executive Roland Diggelmann said in a statement.
 
The Basel-based drugmaker said in August it would buy U.S. biotech company InterMune Inc for $8.3 billion in cash, in a move to expand into the treatment of rare or incurable diseases.
 
(Reporting By Katharina Bart; Editing by Maria Sheahan)

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach